Scancell's chief scientist hails 'excellent' melanoma data
Portfolio Pulse from
Scancell Holdings PLC's chief scientist praised the 'excellent' results from the SCOPE trial for advanced melanoma, which tested the SCIB1 immunotherapy in combination with checkpoint inhibitors ipilimumab and nivolumab.
November 18, 2024 | 7:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scancell Holdings' SCIB1 immunotherapy shows promising results in the SCOPE trial for advanced melanoma, potentially boosting investor confidence.
The positive results from the SCOPE trial for SCIB1 immunotherapy could lead to increased investor confidence and interest in Scancell Holdings, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90